About Us

SinoMab BioScience Limited (“SinoMab” or the “Company”, stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases. The Company’s flagship product SM03 (Suciraslimab) is a global first-in-class anti-CD22 mAb for the treatment of rheumatoid arthritis (RA). SM03 (Suciraslimab) has met its primary endpoint in its Phase III clinical study for the treatment of RA in China in April 2023. On 5 September 2023, the National Medical Products Administration of the People's Republic of China has accepted the biologics license application (BLA) for SM03 (Suciraslimab) in the treatment of RA. Clinical sites inspection and Good Manufacturing Practice (GMP) inspection at our Haikou production base, the two necessary procedures required as part of the BLA approval process, were completed in January 2024.